Patients enrolled in clinical trials often do not match the individual presenting for treatment, who may have more or less severe disease, comorbid conditions, or different demographic characteristics. As a result, uncertainty, debate, and ultimately variations in how these patients are managed occur [1] . An example is the treatment of T1a (>1 and £5 mm) and T1b (>5 and £10 mm), lymph node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer [2, 3] . Six large randomized, controlled trials (RCTs) have demonstrated significant improvements in breast cancer recurrence and death associated with the addition of trastuzumab to chemotherapy in the adjuvant setting [4] [5] [6] [7] [8] . These trials enrolled predominately patients with node-positive disease and, with the exception of the Breast Cancer International Research Group-006 trial, excluded patients with tumors £1 cm in diameter. Historically, the prognosis for patients with T1a,bN0M0 breast cancers (including both HER2-positive and HER2-normal cases) is good. The overall probability of death at 10 years from breast cancer is considerably lower than that from other causes, especially among women >50 years of age [9] . However, recent studies have suggested that patients with HER2-positive T1a,bN0M0 cancers may be at a higher risk for recurrence [10] [11] [12] .
In the absence of level I evidence supporting the use of adjuvant trastuzumab-based chemotherapy in this population, the management of these patients remains controversial. The American Society of Clinical Oncology 2007 recommendations did not advise HER2 testing of the primary tumor 'for solely determining a patient's prognosis' [13] . While the predictive role of HER2 is well established, a systematic review of the literature in 2001 concluded that HER2 was a weak to moderate prognostic factor and advised against its use when making decisions regarding adjuvant systemic therapy [14] . The main The 10-year relapse-free survival and breast cancer-specific survival for T1a,bN0M0 breast cancer without HER2 overexpression was not significantly different from T1a,bN0M0 HER2-positive breast cancer.
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T1a moderately or poorly differentiated = 12; T1b utility of HER2 is to guide whether a patient should receive trastuzumab therapy [15] . As women are living longer with their disease, the long-term treatment effects of therapy, comorbid conditions, and competing causes of death assume increasing importance. This issue is recognized by the National Comprehensive Cancer Network, which considers trastuzumab as an option for HER2-positive tumors between 0.6 and 1 cm, but 'the prognosis of patients with T1a and T1b tumors that are node negative is generally favorable even when HER2 is amplified or overexpressed . the decision to use trastuzumab must be balanced with the known toxicities, such as cardiac toxicity, and the uncertain absolute benefits that may exist with trastuzumab therapy'. This recommendation was coded as category 3 indicating that it is not based on high-level evidence but on expert opinion and generated substantial disagreement between panel members [16] . Trastuzumab-induced cardiotoxicity is idiosyncratic, is unrelated to dose, displays a wide range of severity, and is reversible in most cases but not all cases [17] . However, in the absence of long-term safety data, it remains an important issue [18] [19] [20] . Despite prospective monitoring and exclusion of women with various cardiac conditions in the adjuvant trials, the incidence of cardiotoxicity was significantly higher in the trastuzumab-treated arms with up to 4% developing severe congestive heart failure and a larger number developing asymptomatic decreases in left ventricular ejection fraction (LVEF), the long-term significance of which is unknown [21, 22] .
Several retrospective studies have examined the role of HER2 as a prognostic marker in T1a,bN0M0 breast cancer ( Table 1) . Each of these studies has limitations inherent to retrospective database analyses. The number of T1a,bN0M0 HER2-positive cases is low even in the largest retrospective datasets, leading to wide confidence intervals around the point estimates. Small cohort sizes may reflect the rarity of this disease subset; however, the lack of systematic HER2 testing of older specimens also contributes to underrepresentation of this subset in clinical databases and raises the potential for ascertainment bias. Patients included in databases receive variable adjuvant therapies, including systemic chemotherapy, endocrine therapy, or both. How treatment is selected and why cannot be ascertained and this introduces potential bias into outcome analysis. It is notable that the population of patients who received therapy that would conform to today's practice (e.g. endocrine therapy for all hormone receptor-positive cases) represents relatively small proportions in the currently published studies. Comorbidities are also not recorded systematically or accounted for in the analyses. The definition of cancer-related events [disease-free survival (DFS), recurrence-free survival, etc.] also varies from study to study. Because of these uncertainties, the precise baseline risk for recurrence of T1a,bN0M0 HER2-positive breast cancer treated with locoregional therapy alone is uncertain and it is equally uncertain how this risk improves by adjuvant therapy that does not contain trastuzumab.
However, results from these studies allow some broad generalizations. The 5-year DFS of T1a,bN0M0 HER2-positive breast cancers from the pre-trastuzumab era appears to be between 77% and 95%. Studies that included patients with less systemic therapy tend to report higher rates of recurrence and Abstracts and studies that grouped T1c in with T1a,bN0M0 cancers were not included.
CI, confidence interval; CISH, chromogenic in situ hybridization; DDFS, distant disease-free survival; DFS, disease-free survival; DRFS, distant recurrence-free survival; IHC, immunohistochemistry; NR, not reported; OS, overall survival; RFS, recurrence-free survival.
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Annals of Oncology studies that included patients who mostly received some form of adjuvant therapy report the lowest recurrence rates. The majority of studies report survival rates 90% ( Table 1 ). Studies that report on comparison of outcome between small HER2 -positive and similarly small HER2-negative cancers tend to report a numerically worse outcome for the HER2-positive cohorts, which reaches statistical significance in some but not all studies. To put these results into a broader context, based on surveillance, epidemiology and end results data, for patients with T1a,bN0M0 breast cancers including both HER2-positive and HER2-negative cases treated according to community standards between 1988 and 2001, the 10-year all-cause mortality and breast cancer-specific mortality rates were 24% and 4%, respectively [9] . In younger women (£50 years), the breast cancer-specific mortality can be as high as 11%.
There is no hint from any of the numerous RCTs that the efficacy (i.e. the antitumor activity) of trastuzumab, endocrine therapy, or chemotherapy would depend on tumor size [4, 25, 26] . Therefore, <1 cm tumors are expected to derive the same relative benefit from these adjuvant treatment modalities as larger cancers. Consequently, even the smallest invasive cancer that has the slightest risk for recurrence has a chance that it could benefit from adjuvant systemic therapy. The absolute benefit would vary greatly depending on the baseline risk for recurrence, which is influenced by tumor size among others.
When benefits from therapy are uncertain (e.g. due to uncertain baseline risk estimates), the risks for adverse events from treatment, patient preferences, and cost-effectiveness become increasingly important in decision making.
To help weigh these benefits and risks, we estimated the number needed to treat (NNT) to save one patient from a breast event and the number needed to harm (NNH) by causing one adverse cardiac event (CE) ( Table 2) . We assumed that the relative risk (RR) reduction associated with trastuzumab-based therapy would be the same across all prognostic risk levels based on tumor size. We used the RRs from the Dahabreh et al. [21] meta-analysis. Absolute differences in outcome were calculated using [exp (RR · ln (control survival)) 2control survival] [33] and the NNT was calculated as follows: NNT = 1/absolute benefit [34] . The NNH was calculated using the incidence of CE's in the trastuzumab arm of each adjuvant trastuzumab RCT and assuming the incidence of a CE would be zero in an untreated group (the incidence of a CE according to definitions given in Table 2 range from 0% to 0.7% in the trastuzumab-untreated arms). Table 2 shows that in many instances the NNH (26-250) is much larger than the NNT . However, in certain populations, particularly among those with borderline-normal LVEF (50%-54%) and >50 years of age, the NNH is substantially lower (6) than the NNT . Figure 1 shows that as the absolute risk reduction decreases, the NNT increases and more Definition of a cardiac event (CE) by each trial-HERA: severe congestive heart failure (CHF), which does not include death from cardiac causes, defined as New York Heart Association (NYHA) grade III or IV functional class confirmed by a cardiologist and a decrease in LVEF of at least 10% below baseline and to <50%. Symptomatic CHF was defined as symptomatic congestive heart failure confirmed by a cardiologist and LVEF <50% and a decrease in LVEF of at least 10% from baseline [29, 30] . NSABP B31: defined as NYHA class III or IV CHF or possible/probable cardiac death [28] . NCCTG N9831: defined as NYHA class III or IV CHF or possible/probable cardiac death [27] . BCIRG 006: cardiac death or grade 3/4 CHF, grade 3/4 cardiac ischemia/infarction, grade 3/4 arrhythmia (grade 3 CHF is symptomatic CHF responsive to treatment, LVEF between 20% and 39%; grade 4 CHF is refractory CHF, LVEF <20%) [31] .
a Tan-Chiu et al. [32] analysis of cardiac dysfunction in the NSABP B31 trial reported that among the 48 patients of age 50 years with LVEF £54%, 9 experienced CHF, all within 7 months of initiating trastuzumab (cumulative incidence = 20%; 95% CI 11% to 36%). AC-DH, doxorubicin, cyclophosphamide-docetaxel, trastuzumab; AC-TH, doxorubicin, cyclophosphamide-paclitaxel, trastuzumab; CI, confidence interval; CT-H, chemotherapy-trastuzumab; DFS, disease-free survival; DRFS, distant recurrence-free survival; HR, hormone receptor; LVEF, left ventricular ejection fraction; NNH, number needed to treat harm one patient; NNT, needed to treat for one patient to benefit; RFS, recurrence-free survival; TCH, docetaxel, carboplatin, trastuzumab.
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patients are exposed to the adverse effects of therapy. As the risk for a CE increases due to comorbid conditions or advancing age, the NNH falls ( Figure 2 ) and at some point the NNH and the NNT overlap (Figure 3 ). These results highlight the need for careful medical judgment when selecting patients with TabN0M0 cancer for adjuvant trastuzumab. A blanket recommendation to treat all small HER2-positive breast cancer with trastuzumab-based therapy will almost certainly lead to clinically significant cardiotoxicity in some without any benefit in breast cancer recurrence. Similarly, withholding this form of adjuvant therapy from all small HER2-positive cancers will result in some otherwise avoidable breast cancer recurrence. Unfortunately, today we do not have accurate tools to identify precisely the subset of patients for whom the risks of trastuzumab outweigh the benefits. Currently available data suggest that the patient population in whom the risk/benefit ratio of trastuzumab-based adjuvant chemotherapy is the least favorable includes women who are >50 years of age and/or have borderline LVEF (50%-54%).
Shared medical decision making should incorporate estimates of the risk for a CE using risk calculators similar to Adjuvant! online [35] , e.g. http://www.americanheart.org/ gglRisk/locale/en_US/ or http://www.cardiosmart.org/, and these risks should also be discussed and explored with patients in order for them to make informed choices based on their own perspectives and risk tolerance levels, and if trastuzumab-based therapy is considered, regimens with lowest risk of cardiotoxicity should be considered [36, 37] .
It is unlikely that an RCT would ever be conducted for this subset to establish or refute the benefit from adjuvant trastuzumab. Estimates of the risk/benefit ratio could be further optimized by the development of molecular predictors of prognosis within the HER2-positive disease [38] . In addition, it would be very important to develop better prediction tools to estimate more precisely the risk for death from comorbid illnesses and in particular the risk for cardiac death. Until such a multivariate adverse event prediction tool becomes available, treatment selection for T1a,bN0M0 HER2-positive cancers remains at the transition zone of evidence-and subjective judgment-based-medicine. The number needed to treat to harm as a function of the risk for a cardiac event (CE). The graph illustrates the number needed to treat to cause a CE (R) and where the number needed to harm = 1/R. We assumed the risk in the control group (trastuzumab untreated) as zero. If the risk of a CE associated with chemotherapy -trastuzumab is 5%, we would need to treat 20 patients to harm 1, and if the risk is 10%, we would need to treat 10 patients to harm 1. Figure 3 . The number needed to treat (NNT) to benefit or harm and when they might overlap. Here, we superimpose the two previous graphs, such that the x-axis is survival in the control group (trastuzumab untreated) for NNT to benefit and it is the risk of cardiac events (CEs) in the treated group for number needed to harm (NNH). The curves cross at 0.177 when NNT = NNH = 5.7. We harm more patients than we benefit when the risk of a CE in the treated group is greater than 17.7%. (S) ) 2S] such that RR = 0.6. The graph is based on an expected RR reduction of 0.6 with chemotherapy-trastuzumab. If we assume that an untreated patient with a T1a,bN0M0 HER2-positive breast cancer (control survival) has an expected overall survival (OS) of 90%, then we would need to treat 26 patients for 1 to benefit from therapy, and if the expected OS was 80%, then we would need to treat 13 patients for 1 to benefit. RR, relative risk.
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